Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04501978 · ClinicalTrials.gov registry record · Phase 3
ACTIV-3: Therapeutics for Inpatients With COVID-19
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,753
- Enrollment target
NCT04501978: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT04501978 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,753 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (257% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04501978, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,753 participants
- Enrollment target
Study Summary
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC.
Primary Outcome
Sustained recovery defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to Day 90.
Interventions
- DRUG Placebo
- BIOLOGICAL Remdesivir
- BIOLOGICAL VIR-7831
- BIOLOGICAL LY3819253
- BIOLOGICAL BRII-196/BRII-198
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,753 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2023-07-14 |
| Phase | Phase 3 |
What the finished NCT04501978 record still lists
NCT04501978 is an interventional study that assigns participants to a tested intervention. Its 2,753 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (257% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04501978 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04501978 about?
NCT04501978 is a clinical study titled "ACTIV-3: Therapeutics for Inpatients With COVID-19". This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC.
What is the current status of trial NCT04501978?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,753 participants. The study started on 2020-08-04. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT04501978?
The interventions under investigation include: Placebo (DRUG), Remdesivir (BIOLOGICAL), VIR-7831 (BIOLOGICAL), LY3819253 (BIOLOGICAL), BRII-196/BRII-198 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04501978?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04501978's enrollment target sits among peer trials
2,753 82nd of 2000 higher than 1,918 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI